Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Olympus Corp ADR (OLYMY)

Olympus Corp ADR (OLYMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
EAGLE Trial Shows Olympus(R) CADDIE(TM) AI Solution Aids in the Detection of High-Risk and Hard-to-Detect Colorectal Lesions JCN Newswire - Mon Feb 2, 7:00PM CST

EAGLE Trial Shows Olympus(R) CADDIE(TM) AI Solution Aids in the Detection of High-Risk and Hard-to-Detect Colorectal Lesions

OLYMY : 8.7000 (+4.07%)
OCPNF : 8.2075 (+2.59%)
Olympus Triples Venture Capital Fund Investment to Strengthen MedTech Leadership JCN Newswire - Sun Dec 14, 2025

Olympus Triples Venture Capital Fund Investment to Strengthen MedTech Leadership

OLYMY : 8.7000 (+4.07%)
OCPNF : 8.2075 (+2.59%)
Olympus Unveils Corporate Strategy JCN Newswire - Fri Nov 7, 2025

Olympus Unveils Corporate Strategy

OLYMY : 8.7000 (+4.07%)
OCPNF : 8.2075 (+2.59%)
Olympus Introduces NBI+TXI(TM) Observation Mode to the EVIS X1(TM) Endoscopy System CV-1500 Video System Center JCN Newswire - Tue Oct 28, 2025

Olympus Introduces NBI+TXI(TM) Observation Mode to the EVIS X1(TM) Endoscopy System CV-1500 Video System Center

OLYMY : 8.7000 (+4.07%)
OCPNF : 8.2075 (+2.59%)
Olympus Launches New Surgical Energy Device for Hemostatic Cutting and Vessel Sealing JCN Newswire - Tue Oct 21, 2025

Olympus Launches New Surgical Energy Device for Hemostatic Cutting and Vessel Sealing

OLYMY : 8.7000 (+4.07%)
OCPNF : 8.2075 (+2.59%)
Olympus: "Feasibility study on the development of Japanese digitalized endoscopy infection control systems in India" Selected for METI's FY2024 Supplementary "Global South Future-Oriented Co-Creation Subsidy Program (Small-Scale Demonstration / JCN Newswire - Mon Oct 20, 2025

Olympus: "Feasibility study on the development of Japanese digitalized endoscopy infection control systems in India" Selected for METI's FY2024 Supplementary "Global South Future-Oriented Co-Creation Subsidy...

OLYMY : 8.7000 (+4.07%)
OCPNF : 8.2075 (+2.59%)
Macquarie Sticks to Its Hold Rating for Olympus (OCPNF) Tipranks - Wed Oct 15, 2025

In a report released today, Tony Ren from Macquarie maintained a Hold rating on Olympus, with a price target of Yen2,000.00. The company’s shares closed last Tuesday at $12.42.Elevate Your Investing...

OLYMY : 8.7000 (+4.07%)
OCPNF : 8.2075 (+2.59%)
Olympus Launches SecureFlex, a Single-use Fine Needle Biopsy Device JCN Newswire - Mon Oct 6, 2025

Olympus Launches SecureFlex, a Single-use Fine Needle Biopsy Device

OLYMY : 8.7000 (+4.07%)
OCPNF : 8.2075 (+2.59%)
Olympus (OCPNF) Receives a Buy from J.P. Morgan Tipranks - Fri Oct 3, 2025

In a report released today, Naoko Saito from J.P. Morgan maintained a Buy rating on Olympus, with a price target of Yen2,100.00. The company’s shares closed last Tuesday at $12.42.Elevate Your Investing...

OLYMY : 8.7000 (+4.07%)
OCPNF : 8.2075 (+2.59%)
Olympus Launches OLYSENSE CAD/AI in the US and Europe JCN Newswire - Tue Sep 30, 2025

Olympus Launches OLYSENSE CAD/AI in the US and Europe

OLYMY : 8.7000 (+4.07%)
OCPNF : 8.2075 (+2.59%)

Barchart Exclusives

As Applied Materials Raises Its Dividend 15%, Should You Buy AMAT Stock? Barchart - Tue Mar 17, 6:30PM CDT
Applied Materials' 15% dividend hike to $0.53 per share, backed by a forward payout ratio of under 19% and an 18% annualized growth rate over the past decade, signals a company confident enough in its AI memory and logic tool cycle to keep rewarding shareholders. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot